Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
Dyne Therapeutics, focused on innovative therapies for muscle diseases, announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics, focused on innovative therapies for muscle diseases, announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference. Management, including CEO Joshua Brumm and CSO Oxana Beskrovnaya, will engage in a fireside chat on October 5, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on Dyne's website, with replay access for 90 days. Dr. Beskrovnaya will also speak in a panel on RNA-based delivery approaches. The company is advancing therapeutics for conditions like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Details
News Market Reaction – DYN
The recorded move for DYN in the trading session of this news was -0.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during Chardan’s Virtual 5th Annual Genetic Medicines Conference.
Joshua Brumm, Dyne’s president and chief executive officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, will participate in a fireside chat on October 5, 2021 at 9:00 a.m. ET. A live webcast of the chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
Dr. Beskrovnaya is also an invited speaker on a panel, “RNA-based Targeted Delivery Approaches,” which will be available to conference participants.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.